146
Views
6
CrossRef citations to date
0
Altmetric
Review

New developments in the management of moderate-to-severe hemophilia B

&
Pages 27-38 | Published online: 01 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Massimo Franchini, Marco Zaffanello & Daniele Focosi. (2023) Current factor IX replacement options for hemophilia B and the challenges ahead. Expert Opinion on Pharmacotherapy 24:6, pages 729-736.
Read now
Kamilla Swiech, Virgínia Picanço-Castro & Dimas Tadeu Covas. (2017) Production of recombinant coagulation factors: Are humans the best host cells?. Bioengineered 8:5, pages 462-470.
Read now
Claudia Djambas Khayat. (2016) Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. Journal of Blood Medicine 7, pages 275-282.
Read now

Articles from other publishers (3)

T. Preijers, M. W. F. van Spengler, K. Meijer, K. Fijnvandraat, K. Fischer, F. W. G. Leebeek, M. H. Cnossen & R. A. A. Mathôt. (2021) In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients. European Journal of Clinical Pharmacology 78:2, pages 237-249.
Crossref
Henrike Kuder, Liubov Sandzhieva-Vuzzo, Alexandra Kehl, Jonathan M. Rappaport, Elisabeth Müller & Urs Giger. (2021) A Single Base Insertion in F9 Causing Hemophilia B in a Family of Newfoundland–Parti Standard Poodle Hybrid Dogs. Genes 12:10, pages 1491.
Crossref
Tim Preijers, Laura Bukkems, Max van Spengler, Frank Leebeek, Marjon Cnossen & Ron Mathôt. (2021) In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. European Journal of Clinical Pharmacology 77:8, pages 1193-1200.
Crossref